Navigation Links
Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
Date:8/4/2009

and investment securities $49,909 $72,755 Cash - restricted 281 281 Facilities and equipment, net 331 1,123 Licensed products, net 8,199 8,807 Other assets 1,103 1,266 ----- ----- Total assets $59,823 $84,232 ======= ======= LIABILITIES AND SHAREHOLDERS' EQUITY: Current liabilities $18,456 $19,178 Long term liabilities 13,496 17,407 Shareholders' equity 27,871 47,647 ------ ------ Total liabilities and shareholders' equity $59,823 $84,232 ======= ======= Note 1: Derived from audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2008.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
2. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
3. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
4. Poniard Pharmaceuticals Files Shelf Registration
5. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
6. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
7. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
8. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
9. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
10. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
11. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
(Date:10/22/2014)... October 22, 2014 WriteResult, LLC ... – has been working with a team of researchers ... Haven Farms Community Farming Collaborative to provide electronic questionnaire ... The study, which started in May, aims to ... provides participants weekly exposure to and participation in urban ...
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... SALT LAKE CITY, March 17 Axial Biotech, ... of molecular diagnostics,and motion preserving technologies, announced today ... its development of the first genetic,prognostic test for ... million tranche of its Series B financing. The ...
... Declares Preferred Stock Dividend -, SAN DIEGO, Calif., ... ) today announced that its board of directors has,declared ... of common stock,an 8.1% increase over the company,s previous ... equivalent to an annualized dividend,of $1.34 per common share., ...
... IRVINE, Calif., March 14 Masimo Corporation,(Nasdaq: MASI ), ... pulse oximetry, today announced that it is scheduled,to present at ... The Four Seasons Hotel in Las Vegas, NV on Wednesday, ... and CEO, and Mark P. de,Raad, Executive Vice President and ...
Cached Biology Technology:Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing 2BioMed Realty Trust Announces Increase in Quarterly Common Stock Dividend 2Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference 2
(Date:10/19/2014)... in India over the last 30 years contributed ... growth during that time, according to a new ... Change ., "Energy access is fundamental to development: ... including education, communication, and health," says IIASA researcher ... increased energy access is widely agreed to be ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
(Date:10/16/2014)... have a new synthesis of recent research findings to ... in the two states. , The Ecology and ... Washington: A Synthesis of the Relevant Biophysical Science and ... published by the U.S. Forest Service,s Pacific Northwest Research ... managers for a synthesis of the large body of ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Sperm wars 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... sea ice in the Arctic has shrunk to its ... 30 years ago, opening up the Northwest Passage ... has been historically impassable. In the mosaic image ... September 2007 by the Advanced Synthetic Aperture Radar (ASAR) ...
... 2007 American Society for Microbiology (ASM) sanofi-aventis U.S. ... M.D., Ph.D., Chief, Laboratory of Malaria and Vector ... Bethesda, Maryland. Supported by an unrestricted grant ... in antimicrobial chemotherapy. Dr. Wellems has had ...
... and volunteers who helped in the clean-up effort after ... of Spain exhibit prolonged respiratory symptoms resulting from their ... to examine the long-term effects of such exposures on ... reported in the second issue for September of the ...
Cached Biology News:Satellites witness lowest Arctic ice coverage in history 2Prolonged respiratory problems for oil spill clean-up volunteers 2Prolonged respiratory problems for oil spill clean-up volunteers 3
... is described by end-users to be "a ... fundamentals of light microscopy and electronic imaging. ... it does not require much space and ... lab environment. The DM-BA300 combines Motic's own ...
... Overhead Drive for individual and parallel agitation ... agitation of DASGIP vessels, featuring range of ... ,Up to 16 overhead drives can be ... Systems fedbatch-pro® and cellferm-pro® for microbiology and ...
... Life Science LAS-3000 imaging system combines ... simplified user interface, providing significantly improved ... of modularities. The system is especially ... perfect standard system for Western blotting ...
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
Biology Products: